Special Issue

Zebrafish Models: From Basic Research to Translational Medicine

Message from the Guest Editors

Zebrafish have emerged as a powerful model organism in biomedical research, bridging the gap between basic science and clinical applications. With its high genetic homology to humans, rapid development, transparency, and suitability for high-throughput screening, the zebrafish model offers unique advantages for studying developmental biology, disease mechanisms, drug discovery, and toxicology. In recent decades, zebrafish have made significant contributions to breakthroughs in cancer research, neurobiology, cardiovascular disease, and regenerative medicine. This Special Issue aims to collate innovative research that demonstrates the utility of zebrafish models in advancing our understanding of human diseases and therapeutic development. The scope of this Special Issue aligns with the journal's focus on experimental and translational biology, covering molecular mechanisms, disease modeling, drug screening, and biomedical applications. For this Special Issue, original research articles and reviews are welcome to be submitted. We look forward to receiving your contributions and collaborating with you to advance the field of zebrafish biomedical research.

Guest Editors

Dr. Surendra Rajpurohit
Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA

Prof. Dr. Vishal Arora
Division of Cardiology, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

Deadline for manuscript submissions

31 March 2026

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).